Patients studied in the GADOLIN trial

The follicular lymphoma patients studied in this trial were refractory to rituximab-containing regimens that primarily included R-CHOP, R-CVP, and rituximab monotherapy 1,2

GAZYVA GADOLIN Patient Population Image

Only 2 patients enrolled into the trial had prior bendamustine exposure.
R-CHOP, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone;
R-CVP, rituximab, cyclophosphamide, vincristine sulfate, and prednisone.

GAZYVA GADOLIN Takeaway Pre-planned Interim Analysis Image